Arizona heart centre to use CardioDx's CAD gene expression test
This article was originally published in Clinica
Executive Summary
The Heart & Vascular Center of Arizona has become one of the first institutions to offer CardioDx's Corus CAD blood test. The "first-of-its-kind" gene expression test assesses the likelihood of obstructive coronary artery disease (CAD) in patients with stable chest pain, by measuring expression levels of 23 genes. It is intended for use with standard clinical assessments, and could be more objective and safer for patients that conventional imaging technologies, CardioDx hopes. The firm launched Corus CAD in nine US states in August after completing a validation study, and plans to expand the availability of the test in 2010. CardioDx processes samples at its CLIA-certified lab in Palo Alto, California.